MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: February 16, 2010

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/580,646
Filing Date	02/06/2007
First Named Inventor	Glynne Ivo GUT
Group Art Unit	1637
Examiner Name	Heather Calamita
Attorney Docket Number	065691-0447

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A1	WO	00/65088	A	Amersham Pharm. Biotech. AB	11/02/2000		
	A2	WO	02/08462	A	Lechner et al.	01/31/2002		
	A3	WO	02/18659	A	Haplogen LLC	03/07/2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A4	PASTINEN et al., "Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation," *Clinical Chemistry*, American Association for Clinical Chemistry, vol. 42, no. 9, 1996, pp. 1391-1397.	
	A5	WORRALL et al., "Allele-specific HLA-DR typing by mass spectrometry: an alternative to hybridization-based typing methods," *Analytical Chemistry*, November 1, 2000, vol. 72, no. 21, pp. 5233-5238.	
	A6	LEUSHNER et al., "Automated mass spectroscopic platform for high throughput DR Beta typing," *Human Immunology*, vol. 61, no. Supplement 2, 2000, p. S126.	
	A7	TOST et al., "Genotyping single nucleotide polymorphisms by mass spectrometry," *Mass Spectrometry Reviews*, vol. 21, no. 6, November 2002, pp. 388-418.	
	A8	TOST et al., "Molecular haplotyping at high throughput," *Nucleic Acids Research*, October 1, 2002, vol. 30, no. 19, p. e96.	
	A9	SAUER et al., "Extension of the good assay for genotyping single nucleotide polymorphisms by matrix-assisted laser desorption/ionization mass spectrometry," *Rapid Communications in Mass Spectrometry*, vol. 17, no. 12, May 9, 2003, pp. 1265-1272.	
	A10	SAUER et al., "Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry," *Journal of Chromatography B*, Analytical Technologies in the Biomedical and Life Sciences, December 25, 2002, vol. 782, no. 1-2, pp. 73-87.	
	A11	ROZEMULLER, "Reference panels for sequence based typing: Selection criteria for HLA-A and HLA-B," 2000, retrieved from the Internet: URL:http://wwww.ihwg.org/tmanual/TMcontents.htm, retrieved on 07/05/2004.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: February 16, 2010

(use as many sheets as necessary)

Sheet | 2 | of | 2

Complete if Known	
Application Number	10/580,646
Filing Date	02/06/2007
First Named Inventor	Glynne Ivo GUT
Group Art Unit	1637
Examiner Name	Heather Calamita
Attorney Docket Number	065691-0447

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A12	ROSS ET AL., "Discrimination of Single-Nucleotide Polymorphisms in Human DNA Using Peptide Nucleic Acid Probes Detected by MALDI-TOF Mass Spectrometry," *Anal. Chem.,* Vol. 69, pp. 4197-4202, 1997.	
	A13	ROSS ET AL., "High level multiplex genotyping by MALDI-TOF mass spectrometry," *Nature Biotechnology,* Vol. 16, pp. 1347-1351, December 1998.	
	A14	ROBINSON ET AL., "Exon Identities and Ambiguous Typing Combinations," *Anthony Nolan Research Institute,* October 2003.	
	A15	PETERSDORF ET AL., "Tissue typing in support of unrelated hematopoietic cell transportation," *Tissue Antigens,* Vol. 61, pp. 1-11, 2003.	
	A16	LIU ET AL., "Rapid Screening of Genetic Polymorphisms Using Buccal Cell DNA with Detection by Matrix-assisted Laser Desorption/Ionization Mass Spectrometry," *Rapid Communications in Mass Spectrometry,* vol. 9, pp. 735-743, 1995.	
	A17	LITTLE ET AL., "Detection of RET proto-oncogene codon 634 mutations using mass spectrometry," *J. Mol. Med.,* Vol. 73, pp. 743-750, 1997.	
	A18	HAFF ET AL., "Single-Nucleotide Polymorphism Identification Assays Using a Thermostable DNA Polymerase and Delayed Extraction MALDI-TOFF Mass?Spectrometry," *Genome Research,* Vol. 7, pp. 378-388, 1997.	
	A19	GRIFFIN ET AL., "Genetic analysis by peptide nucleic acid affinity MALDI-TOF mass spectrometry," *Nature Biotechnology,* Vol. 15, pp. 1368-1372, December 1997.	
	A20	FEI ET AL., "MALDI-TOF mass spectrometric typing of single nucleotide polymorphisms with mass-tagged ddNTPs," *Nucleic Acids Research,* Vol. 26, No. 11, pp. 2827-2828, 1998.	
	A21	CH'ANG ET AL., "Detection of ΔF508 Mutation of the Cystic Fibrosis Gene by Matrix-assisted Laser Desorption/Ionization Mass Spectrometry," *Rapid Communications in Mass Spectrometry,* vol. 9, pp. 772-774, 1995.	
	A22	KARAS ET AL., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeing 10,000 Daltons," *Anal. Chem.,* Vol. 60, pp. 2299-2301, 1988.	
	A23	TOST ET AL., "Genotyping Single Nucleotide Polymorphisms by Mass Spectrometry," *Mass Spectrometry Reviews,* Vol. 21, pp. 388-418, 2002.	
	A24	International Search Report issued on 07/11/2005 for application number PCT/IB2004/004115.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.